Horizon Europe is the ambitious EU key research and innovation framework programme for 2021 to 2027 with a budget of €95.5 billion. Their related projects involve an important challenge in terms of management of relationships between partners and their innovative character thereof. They imply development of innovative products that are expressly complex in its nature (tissue engineered products, cell therapies, complex biomaterials, nanomaterials, gene therapy, digital health, among others), research environments, manufacturing conditions and potential health applications, to which specific regulatory conditions apply.
For a project to be feasible for the European Commission, a sustained regulatory support is key to confer projects with consistency according to call standards.
Therefore, in order to ensure a proper profiling and regulatory compliance of the product, from development to potential future commercialization, involving a regulatory partner as Asphalion is of paramount interest when it comes to Horizon Europe, both for grant obtention and for a successful project execution.
Horizon Europe EU-funded Programmes Solutions
Support in proposal preparation as regulatory expert, including:
Regulatory activities during project execution:
Asphalion collaborates with leading universities and research institutions to foster innovation and knowledge exchange in the life sciences sector. Through these partnerships, we contribute our regulatory and scientific expertise while supporting education and research initiatives.
Take a look at some of the partners we have collaborated with so far:
Schedule a free meeting!
Discuss your case with our experts and receive a valuable feedback
Downloads
Share
Why Asphalion?
With more than 150 professionals with scientific and regulatory background, Asphalion is currently involved in 16 European funded projects as global regulatory partners, taking care of the activities during the development of different innovative medicinal products and medical applications, tailored specifically for each call .
Some of these projects include ATMPs development, COVID-19 indicated products, therapeutic vaccines, microbiome products, complex biomaterials and implants, gene therapies or multimodal nanoparticles, among others, all of them oriented towards different stages of the development process from pre-clinical research to clinical setting.
This expertise backs Asphalion as a top-class regulatory partner to fulfill with the requirements that best position the regulatory strategy of your Horizon Europe Consortium.
Related Resources
Highlights video
Highlights video
Highlights video
Highlights video
Highlights video
Highlights video
Asphalion contributions to the fight against COVID-19
Asphalion Contributes to a Joint EU Policy Brief Supporting a Greener Pharmaceutical Future
This week, our regulatory experts, Maria Castellà and Alejandro Ballester, participated in the first consortium meeting of the EU-funded GreenNanoBone project in Bergen, Norway. Two key highlights from the meeting:
The objective of this project is to create a siRNA-combined advanced therapy, which will allow a more personalised treatment for the different stages of osteoarthritis. All siNPAIN partners are working hard to develop an efficient therapy to improve the quality of life of those affected by osteoarthritis, a chronic joint condition that affects more and more people every year.
Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts.
We will be happy to assist you!
